Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 10,000 shares at $1.85 ($18K) on 2015-08-04, disclosed to the SEC on 2015-08-06.
Scheduled sale ($18k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.84 | 4,900 | $9K | 48.9% |
| 2 | $1.85 | 100 | $185 | 1.0% |
| 3 | $1.85 | 5,000 | $9K | 50.1% |
| Total | $1.85 avg | 10,000 | $18K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |